Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2445 August 2025

PATIENT NHI: **APPLICANT** (stamp or sticker acceptable) REFERRER Reg No: First Names: First Names: Surname: Surname: Address: Fax Number: Fax Number: **Long-acting Somatostatin Analogues** Initial application — Malignant Bowel Obstruction Applications from any relevant practitioner. Approvals valid for 2 months. **Prerequisites**(tick boxes where appropriate) The patient has nausea* and vomiting* due to malignant bowel obstruction* and Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has not been and Treatment to be given for up to 4 weeks Note: Indications marked with * are unapproved indications. Renewal — Malignant Bowel Obstruction Current approval Number (if known):..... Applications from any relevant practitioner. Approvals valid for 3 months. Prerequisites(tick box where appropriate) The treatment remains appropriate and the patient is benefiting from treatment Initial application — Acromegaly Applications from any relevant practitioner. Approvals valid for 3 months. Prerequisites(tick boxes where appropriate) The patient has acromegaly and Treatment with surgery and radiotherapy is not suitable or was unsuccessful or Treatment is for an interim period while awaiting the beneficial effects of radiotherapy and Treatment with a dopamine agonist has been unsuccessful Renewal — Acromegaly Current approval Number (if known):..... Applications from any relevant practitioner. Approvals valid for 2 years. Prerequisites(tick box where appropriate) IGF1 levels have decreased since starting treatment Note: In patients with acromegaly, treatment should be discontinued if IGF1 levels have not decreased 3 months after treatment. In patients treated with radiotherapy treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following treatment withdrawal for at least 4 weeks

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2445 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:
Reg No:	First Names:	First Names:
Name:	Surname:	Surname:
Address:	DOB:	Address:
	Address:	
Fax Number: Long-acting Somatostatin Analogues -		Fax Number:
Initial application — pre-operative acromegaly Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate) Patient has acromegaly and		
Patient has a large pituitary tumour, greater than 10 mm at its widest and Patient is scheduled to undergo pituitary surgery in the next six months		
Initial application — Other Indications Applications from any relevant practitioner. Approvals valid for 2 years. Prerequisites(tick boxes where appropriate) VIPomas and Glucagonomas - for patients who are seriously ill in order to improve their clinical state prior to definitive surgery or Gastrinoma and Surgery has been unsuccessful or Patient has metastatic disease after treatment with H2 antagonist or proton pump inhibitors has been unsuccessful or Insulinomas and Surgery is contraindicated or has not been successful or Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis) and Disabling symptoms not controlled by maximal medical therapy		
Note: The use of a long-acting somatostatin analogue in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded under Special Authority		
Renewal — Other Indications Current approval Number (if known):		

I confirm the above details are correct and that in signing this form I understand I may be audited.